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Abstract
Background: Liver resection of large hepatocellular carcinomas (HCC), measuring at least 10 cm
remains a controversial debate. Multiple studies on HCCs treated with surgical resection and/or ablation
had shown variable results with 5-year survival rates ranging from 0% to 54.0%. The aim of this study was
to evaluate the survival of patients with HCCs measuring at least 10 cm and to identify the potential
prognostic variables affecting the outcome.
Methods: Retrospective analysis was performed on the prospectively updated HCC database. A total of
44 patients with tumours measuring 10 cm or more were ‘curatively’ treated with surgical resection with
or without ablation. Patient demographics, clinical, surgical, pathology and survival data were collected
and analysed.
Results: Thirty-one patients received surgical resection alone. Thirteen other patients were treated with
a combination of surgical resection and ablation. The median follow-up duration was 14.5 months. The
overall median survival at 1, 3 and 5 years were 66.4%, 38.1% and 27.8%, respectively. The median time
to tumour recurrence was 10.7 months and the 1, 3 and 5-year disease-free survival were 49.6%, 23.9%
and 19.1%, respectively.
Univariate analysis demonstrated cirrhosis, microvascular invasion, poor tumour differentiation and
ethnicity to adversely affect survival. For overall survival, only cirrhosis, poor tumour differentiation and
ethnicity were significant on multivariate analysis. Portal vein tumour thrombus, microvascular invasion
and ethnicity were identified on univariate analysis to significantly affect disease-free survival.
Conclusion: Surgical treatment offers good survival to patients with large HCCs (10 cm). Both cirrho-
sis and poor tumour differentiation are independent variables prognostic of adverse survival.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world. Despite advances in imaging technolo-
gies, a significant proportion of HCCs are inoperable as a result of
advanced stages at time of diagnosis.1 To date, liver transplant,
surgical resection and local ablative therapies (cryotherapy and
radiofrequency ablation) are the most effective treatments avail-
able, offering a chance of cure to HCC patients. Other alternatives
such as transarterial chemoembolization (TACE), percutaneous
ethanol injection, acetic acid injection and intra-arterial lipiodol
I131 are not as effective in achieving complete tumour eradication,
particularly in large tumours.2,3
Tumour size plays a significant role in the decision making of
treatment preference. Previously, large HCCs (>10 cm) were often
not treated leading to the associated poor prognosis within this
cohort of patients. Amidst the availability of effective surgical
treatments, tumour size of over 10 cm precludes the eligibility for
liver transplant or thermal ablative therapies. While hepatectomy
of smaller tumours (<10 cm) is commonly performed with 5-year
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survival rates ranging from 11% to 58%, surgical resection of large
tumours remains controversial.4–6 Several studies have identified
tumour size as prognostic of adverse survival. Others, however,
showed that liver resection of non-vascular-involved solitary
HCCs (Stage T1) can achieve good long-term outcome, irrespec-
tive of tumour size.7
The purpose of this study was to evaluate the outcome of
therapy in patients with HCCmeasuring at least 10 cm,which was
regarded by most surgeons as inoperable; and to identify prog-
nostic factors for survival.8,9
Methods
This is a retrospective study of a prospectively updated database.
Since January 1990, a total of 349 patients with hepatocellular
carcinoma (HCC) had been looked after by the St George Hospital
Liver Unit. Of these, 110 patients were ‘curatively’ treated with sole
surgical resection or combined surgical resection and ablation.
Treatment was regarded as potentially curative as long as the liver
was macroscopically clear of tumour post-surgery; which was
confirmed intra-operatively with ultrasonography.Determination
of the extent of liver resection was adopted from the study by
Imamura et al.10 The decision to perform synchronous liver resec-
tion and ablative therapies was based on the anatomical location
of tumours; aiming to preserve sufficient post-operative liver
parenchyma. Edge ablations were indicated for cases with a mac-
roscopically close resection margin.
Our selection criteria for ‘curative’ surgical treatment included
absence of extrahepatic disease and preserved liver function
(Child’s A and B). Extent of disease was assessed by lipiodol CT,
chest/abdominal/pelvic CT, bone scans and, if required, CT
angiography. Preservation of liver function was established with
Child’s score and ICG retention in cirrhosis. Child’s score for all
patients was summated based on two clinical (ascites and
encephalopathy) and three biochemical factors (serum bilirubin,
albumin level and international normalized ratio). Suitability of
resection was further determined intra-operatively with ultra-
sound and palpation. Cirrhosis and involvement of portal and
hepatic veins were not absolute contraindications for surgery. All
surgical resections were performed using the cavitron ultrasonic
aspiration (CUSA) technique. All patients were followed up with
serum aFP (alpha-fetoprotein) levels, liver function tests and
abdominal CT scans 1-month post-discharge and at 3-monthly
intervals thereafter. Only patients treated from 1999 onwards were
offered adjuvant lipiodol I131.
Patients with lesions larger than 10 cm, measured at the largest
diameters, were identified and included into study. All files were
reviewed up until 2nd June 2008. Data extracted for analysis
included patient demographics, hepatitis status, Child–Pugh
scoring, pre- and post-operative serum aFP (a-fetoprotein)
levels, type of surgery, histopathology details of resected speci-
mens, disease course and survival.
Hospital deaths, defined as deaths resulting from post-operative
complications and/or those within the same admission, were
included into both overall survival and disease-free survival analy-
sis. Survival analyses, estimated from the date of surgery, were
performed with the Kaplan–Meier survival analysis and compared
with univariate analysis. Multivariate analysis was performed
using a Cox regression model to identify independent variables. A
P-value of <0.05 was considered as significant.All statistical analy-
ses were performed using SPSS for Windows (version 15.0; SPSS
Inc., Chicago, IL, USA).
Results
Patients and treatment modalities
Since 1990, a total of 110 HCC patients had been treated with
surgical resection with or without ablation by the St George
Hospital Liver Unit. Of those, 44 patients were identified to have
lesions of at least 10 cm in diameter, and were included into the
study. A total of 31 patients were solely treated with surgical resec-
tion while 13 others had a combination of surgical resection and
ablation. Ablative techniques performed included eight residual
liver edge ablations with cryotherapy (7) and radiofrequency abla-
tion (RFA) (1), two cryoablations and three alcohol injections to
contralateral lobe lesions. Sixteen patients within this series were
treated adjuvantly with lipiodol I131. Patient demographics and
clinicopathological features of the study group are summarized in
Table 1.
Survival analysis
After a median follow-up duration of 14.5 months (range, 0.03–
169.9 months), two patients were lost to follow up at 76 and 110
months, and were censored in analyses. At the time of analysis,
disease had recurred in 24 patients and 27 had died. The overall
median survival was 21.5 months (range, 0.03–169.9 months),
and the 1-, 3- and 5-year survival rates were 66.4%, 38.1% and
27.8%, respectively (Fig. 1a).
Disease-free survival (DFS) rates at 1-, 3- and 5-years were
49.6%, 23.9% and 19.1%, respectively (Fig. 1b); with a median
time to tumour recurrence of 10.7 months (range, 0.3–169.6
months). Liver recurrence occurred in 13 patients, three of them
at the resection margin or ablation site. Treatment of liver recur-
rence (12) was by lipiodol I131 (5), ablation (3), resection (1) and
chemotherapy (1). Extrahepatic recurrence (3) occurred in the
lungs (2), and peritoneum (1). Patients with recurrence both in
the liver and another site (7) were treated by resection (3) and
chemotherapy (2).
The survival difference between the resection only and synchro-
nous resection and ablation groups was insignificant.
Hospital mortalities
There were a total of eight hospital deaths (18.2%). The causes of
deaths were liver failure in three patients, sepsis and liver failure in
two, hypovolaemic shock in one and non-disease related in two
others. Of the non-disease-related mortalities, one was as a result
of refusal of amputation because of a gangrenous foot. The second
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Table 1 Demographics and clinicopathological characteristics
Parameters Study group Non-cirrhotics
(n = 29)
Cirrhotics
(n = 15)
Age (years)
Median 62.4 62.1 62.3
Range 19.7–87.5 19.7–80.5 32.7–87.5
Gender
Male 33 20 (60.9%) 13 (86.7%)
Female 11 9 (31.0%) 12 (13.3%)
Aetiology
Hepatitis B 15 7 8
Hepatitis C 3 – 3
Alcohol 5 3 2
Haemochromatosis 5 3 2
Unknown 16 16 –
Child–Pugh score
A 35 24 11
B 7 3 4
Unknown 2 2 –
Type of resection
Right hepatectomy 13 6 7
Left hepatectomy 4 3 1
Extended right hepatectomy 7 6 1
Extended left hepatectomy 3 3 –
Central resection 3 2 1
Left lateral resection 4 3 1
Segmentectomy 10 6 4
Serum aFP-level (ng/ml)
Median 33.5 33.5 29.0
Range 0.2–168000 2.0–168000 2.0–168000
Tumour size (cm)
Mean (SD) 13.5  3.2 13.2  3.0 14.1  3.7
Median 12.4 12.3 13
Range 10.0–20.0 10.0–20.0 10.0–20.0
No. of lesions
Solitary 23 17 (58.6%) 6 (40%)
Multiple 21 12 (41.4%) 9 (60%)
Lobar involvement
Unilobar 32 21 (72.4%) 11 (73.3%)
Bilobar 12 8 (27.6%) 4 (26.7%)
Ruptured tumours 6 5 (17.2%) 1 (6.7%)
Portal vein thrombus 5 1 (3.4%) 4 (26.7%)
Microvascular invasion 27 16 (48.3%) 11 (73.3%)
Positive margins 22 13 (44.8%) 9 (60.0%)
Histology
Fibrolamellar 8 7 1
Well differentiated 8 6 2
Moderately differentiated 21 10 11
Poorly differentiated 7 6 1
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patient died of hypovolaemic shock following removal of a chest
drain after resolution of a pleural effusion.
Prognostic factors
Fourteen potential prognostic factors were analysed in univariate
analysis for overall survival (Table 2). The presence of cirrhosis
(P = 0.014), microvascular invasion (P = 0.032), poor tumour
differentiation (P < 0.001) and ethnicity (P < 0.001) were signifi-
cantly associated with adverse survival (Fig. 2). In multivariate
analysis, three factors were found to be independently associated
with poorer survival – cirrhosis (hazard ratio, 4.4; 95% CI, 1.078–
9.961; P = 0.036), poor tumour differentiation (hazard ratio,
10.128; 95% CI, 2.510–48.000; P = 0.001) and ethnicity (hazard
ratio, 8.805; 95% CI, 1.547–8.448; P = 0.003). Evaluation of the
same variables identified three factors that significantly reduced
DFS – the presence of portal vein tumour thrombus (P = 0.003),
microvascular invasion (P = 0.038) and ethnicity (P = 0.003).
Analysis of both cirrhotics and non-cirrhotics showed that the
drastic difference in survival rates between groups occurred early,
mainly within the first 3 months post-surgery (Fig. 2a). All five
early post-operative deaths within the cirrhotics were because
of surgical mortalities. One case had intercurrent pulmonary
metastasis, developed 2 weeks post-operatively. This patient had
no evidence of extrahepatic disease on complete pre-operative
workup with CT chest/abdominal/pelvis, lipiodol CT and bone
scans. Comparatively, only two non-cirrhotic patients died within
this period – one from severe blood loss and another from refusal
of gangrenous foot amputation. Further comparison between
groups showed a higher prevalence of vascular invasion and mul-
tinodularity within cirrhotics (Table 1).
Twenty-seven HCCs were identified with microvascular
involvement. A tumour recurred in 16 of them with 50% occur-
rence within the first post-operative year. Five cases also had
apparent portal vein thrombus. Four of which also had a back-
ground of cirrhosis. None of them survived past 1 year. Causes of
deaths were as a result of early disease recurrence in two patients,
liver failure in one and disseminated intravascular coagulation in
another patient. The other case of portal vein tumour invasion
developed in a fibrolamellar HCC. Disease recurred within the
liver and lymph nodes 6 months post-operatively. This patient
received further surgical intervention and is alive until the date
after 8 years from time of first surgery.
Further investigation on the correlation of aFP-level with
tumour histology was performed. No relationship, however, was
demonstrated (Fig. 3).
Discussion
Multiple studies on radical extirpation of large (>10 cm) tumours
have had variable outcomes. The literature on large HCC includes
14 reports including 2749 patients, with 5-year survival rates
ranging from 0% to 54.0%.1,11–23 However, three of these excluded
hospital mortality. All, except one, of these studies looked at
patients treated with surgical resection alone.1,11–22 Pandey et al.
included in their study, patients treated with RFA within the same
surgical procedure.23 Zhou et al. had previously shown survival of
patients treated with resection and cryotherapy were similar to
those treated with resection alone.24 Our series also included a
mixed group of patients surgically treated with resection and/or
ablation. A 5-year survival rate of 27.8%, similar to the other large
HCC studies identified was achieved.
Cirrhosis was identified to independently affect survival of
HCC patients. As most large tumours require major hepatectomy,
the impossibility of liver resection in the presence of cirrhosis
substantiates.25 In addition, the presence of cirrhosis in large
HCCs denies patients of consideration for aggressive management
Figure 1 Survival analysis. (a) Overall survival of large hepatocellular
carcinomas (HCCs) after surgical treatment; (b) disease-free survival
of large HCCs after surgical treatment
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as a result of an increased risk of post-operative hepatic insuffi-
ciency.14 Even when these lesion(s) are amenable to surgical resec-
tion, prognosis is generally poorer.26 In fact, our 5-year survival
rates in cirrhotics and non-cirrhotics were 0% and 39.7%, respec-
tively. The eminent difference between groups was observed in the
first 3 months post-treatment, mainly because of post-operative
complications. This concurs with the expected high post-
operative mortality in cirrhotic liver resection in other studies.14,25
Figure 2 Univariate analysis. (a) Influence of cirrhosis on overall survival; (b) influence of microvascular invasion on overall survival; (c)
influence of tumour histological on overall survival; (d) influence of ethnicity on overall survival.
HPB 317
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In the contrary, Torzilli et al. reported zero mortality in resection
of cirrhotic livers.27
A large proportion of venous involvement is usually found in
multinodular disease and large tumours.28 This feature was noted
within the cirrhotic group.26,29 The involvement of microvascular
invasion commonly present even at early stages of disease
increases the risk of microtumour embolization.28 Recurrence risk
also escalates with evidence of gross vascular involvement, which
indicates advanced stages of disease according to the step-by-step
dissemination theory.28 Five out of the 27 microvascular-involved
tumours had concomitant portal vein thrombus. Both these
factors – microvascular invasion and portal vein thrombus – were
identified to adversely affect disease-free survival. Resection of
tumours in the presence of portal vein tumour thrombus is also
associated with poorer survival, which may explain the much
poorer survival in our cirrhotic group.28–30 Except for the fibrola-
mellar variant, none of the patients with portal vein thrombus
survived past 1 year. Despite these findings, the number compris-
ing this subgroup may have been too small to have influenced
significance on survival in this study.
Ethnicity was identified to independently affect survival.
Regardless of the statistics, reasons for this association are rather
ambiguous andmay possibly be influenced by non-disease-related
factors such as socioeconomic factors.31,32 Hence, further studies
may, therefore, be required to establish this causal relationship.
Survival of patients stratified according to tumour histological
typedemonstrated correlationof poor tumourdifferentiationwith
poorer survival (Fig. 2c).Patientswithfibrolamellar variant tend to
do much better than the classic HCCs.33 Our result also demon-
strated comparable 5-year survival rates with well-differentiated
tumours (50.0%) and fibrolamellar variant (58.3%). Of the eight
well-differentiated tumours, only two arose on a background of
cirrhosis. Nagorney et al. showed that in the absence of cirrhosis,
classic HCCs can result in similar outcome to a fibrolamellar
variant.34 In addition, moderately-differentiated tumours had a
3-year survival of 32.5%. The survival of poorly differentiated
tumour was much worse compared with all other histological
types, and is found to be significant on multivariate analysis. All
seven patients with poorly-differentiated tumours died within 16
months post-surgery. This may be as a result of the increased risk
of microvascular invasion in higher-grade HCCs.35 Oishi et al.
described the association of high-grade HCCs with larger propor-
tions of high (>400 ng/ml)aFP-secretors, early extrahepatic recur-
rences and better liver function.36 These features, however, did not
accurately describe our poorly-differentiated HCCs. Six out of the
sevenpatients hadChild’sA and serumaFP-levels less than400 ng/
Figure 3 Correlation of serum aFP-level with histological subtypes
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ml.Only one patient had anaFP-level of 963 ng/ml and theChild’s
score was unestablished.A total of four patients died of the disease,
which recurred within the first post-operative year but only two
had extrahepatic (lungs) involvements.
The significantly worse prognosis in poorly differentiated
HCCs may imply sensibility in withholding operative treatment
within this subgroup of patients. Hence, the ability to identify
tumour differentiation via pre-operative assessments may be
useful. Currently, imagings with computed tomography and ultra-
sonography are capable of recognizing well-differentiated HCCs
but discerning moderate from poorly differentiated tumours
remains a difficulty.37,38 Percutaneous tumour biopsy may be the
only available technique providing definitive diagnosis of high-
grade tumours but is associated with needle tract implantation.39
This may jeopardize the supposedly better outcome in other his-
tological subtypes. In our study, correlation of serum aFP-levels
with histological subtypes did not yield significant results (Fig. 3).
Other factors such as tumour rupture and positive resection
margins on histological examination have also been described by
others to adversely affect survival.30,40,41 The prognostic significance
of ruptured tumours, however, may have been undervalued by its
low incidence within this series.Although proven safer with staged
liver resection, the outcome of treated ruptured HCCs is generally
poor, particularly after intra-abdominal spreadmanifests.33,40 Four
out of six ruptured tumours were dead at the time of analysis. Two
patients died within the same admission from post-operative
coagulapathy and refusal of ischaemic leg amputation, and two of
disease recurrence. One recurrence involved intra-abdominal
manifestation of disease while the other involved the lungs. Lai and
colleagues showed that a resection margin of more than 0.5 cm
significantly reduces histological margin infiltration, hence a
reduction in both disease-free and overall survival.41 Within this
study, all hepatectomies were performed using CUSA transaction,
which allows a potential margin of at least 1.0 cm.42 In addition,
suspicion of margin involvement immediately post-resection was
further treated with edge ablation. This may in part explain our
good 5-year survival rate (36.1%) which did not differ from the
3-years; within patients with microscopic margin involvement.
Despite surgical treatment, prognosis of HCCs is still poor as a
result of high rates of recurrence. Various agents have thus been
trialled along with surgical resection to improve disease-free sur-
vival and long-term outcome.43–46 A randomized, controlled trial
with adjuvant lipiodol I131 after resection of smaller tumours was
shown to achieve better prognosis in surgically treated HCCs,with
10-year overall and disease-free survival rates of 52.4% and
47.6%, respectively.47 A total of 16 patients in this study group
were identified to have received adjuvant lipidol I131. The 5-year
survival rates in the treated and non-treated groups were 35.5%
and 14.7%, respectively (P = 0.009). Another agent (PI-88) cur-
rently under trial as an adjuvant treatment was shown to have
similar potential benefits.48
Long-term survival can be achieved with surgical treatment of
large HCCs (>10 cm). In addition, the combination of surgical
resection and ablation can achieve similar outcome to treatment
with resection alone, providing a chance for curative treatment in
‘inadequate’ margins and bilobar-involved disease. After surgical
treatment, the administration of adjuvant lipiodol I131 is also effec-
tive, even in large HCCs. Both cirrhosis and poor tumour differ-
entiation were independently associated with adverse survival.
Further studies to identify poor histological subtype of HCCs in
the pre-operative setting may be useful.
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